
Background: Traditional herbal steam inhalation (Nyungu) is a key healthcare practice in Zanzibar for treating respiratory, febrile, and spiritual ailments. Despite its importance, it remains under documented and underutilized in wellness tourism. This study aimed to document the medicinal plants used in Nyungu and explore opportunities for integration into tourism. Materials and Methods: A cross-sectional ethnobotanical survey was conducted in 26 shehias (14 in Unguja and 12 in Pemba). Sixty-eight traditional healers were purposively selected and interviewed using structured questionnaires. Data on plant use, preparation, treated ailments, and commercialization were analyzed using SPSS and Origin software. Results: The study identified 73 and 75 plant species in Unguja and Pemba, respectively. Commonly cited species included Citrus aurantiacus, Azadirachta indica, and Ocimum americanum. The main ailments treated were runny nose (18%), fever (15%), common cold (13%), and spiritual disorders (12%). Treatment regimens varied: most healers in Unguja preferred one-day sessions, while those in Pemba favored three- to seven-day duration. Polyherbal preparations were widely used. Commercialization was limited, with 60% of healers in Unguja and 84% in Pemba not offering services to tourists. Documentation was low, as only 8% (Unguja) and 17% (Pemba) recorded their practices. Conclusion: Nyungu remains a cornerstone of traditional healthcare in Zanzibar and holds promise for wellness tourism. However, poor documentation, limited commercialization, and lack of standardization hinder its development. Phytochemical validation, cultivation of key species, tourism integration, and supportive policies are recommended for sustainable use and cultural preservation.
Background: Solanum erianthum root (SER) extract is used in traditional medicine to treat dysentery, fever and for pain management. This study examined the toxicity and safety profile of ethanol extract of SER in rats. Method: The LD50 of SER was determined using Lorke’s method. Groups of rats were administered 250, 500 or 750 mg/kg of the ethanol extract of SER daily for 28 days, this was followed by 21 days of recovery study. Various endpoints of toxicity on the kidney, liver and brain including haematological and biochemical parameters as well as histopathological examination were assessed. Result: The LD50 of SER was determined to be greater than 5000 mg/kg. There was no significant difference across the weight and haematological parameters as well as the lipid profile across all the doses investigated when compared to control in the repeated dose toxicity and recovery studies. The results of biochemical evaluations of liver and kidney injury biomarkers in the serum suggest varying degree of effects on the organs marked by significant increases in serum AST, ALT, urea and creatinine. Histopathological examination revealed that the extract caused dose dependent inflammation and vascular congestion to the brain, liver, and kidney in the toxicity study. However, these effects resolved significantly in the recovery study. Conclusion: The ethanol extract of SER is safe for acute use but has potential to induce reversible toxic manifestations on the brain, liver and kidney following prolonged repeated administration.
Blood stasis leads to water retention" is a classic theory in Traditional Chinese Medicine (TCM) proposed in the ancient text "Synopsis of the Golden Chamber". This academic concept has traditionally been applied primarily in gynecological clinical diagnosis and treatment. In recent years, this theory has been widely applied in treating traumatic limb edema in orthopedics, demonstrating significant efficacy with minimal adverse reactions. This paper presents a preliminary discussion on the application of this theory in treating traumatic limb edema in orthopedics.
Background:Emilia praetermissa Milne-Redhead,is a fast growing herb that is native to west and central Africa, the leaf is use in the treatment of ulcer, hernia, pain and tumor by traditional healers in these regions. It is explored in thisstudy for its phytochemicals and cytotoxic activities. Materials and Methods:The powdered leaf was screened for phytochemicals using standard methods, while profiling of the methanol extract was done by both Gas Chromatography-Mass Spectrometry (GCMS) and High Pressure Liquid Chromatography (HPLC). Cytotoxic potential was evaluated using Raniceps raninus (Tadpole-fish) at varying doses (20-320 μg/mL) of the extract (methanol) and fractions (ethylacetate and dichloromethane). Results:Tannins, flavonoids, steroids, glycosides, alkaloids and saponins were revealed by the phytochemical screening. The GC-MS analysis identified thirty-three compounds, which include aziridine, benzaldehyde, benzofuran, carbazole, hydroquinone, isopropylidine,indole, piperidine, piperazine,pyrazole, pyridine, pyrrolidine and tetrazole derivatives. Twelve compounds were identified and quantified from the HPLC analysis; coumaric acid (10.2385 μg/ml), cresol (25.7350 ppm), ellagic acid (3.9547 μg/ml), ferulic acid (8.9514 μg/mL), isoflavone (22.7694 ppm), naringenin (14.1526 μg/mL), naringin (5.6179 μg/ml), pyrogallol (12.5850 μg/g), resveratrol (3.8639 ppm) and salicylic acid (17.4195 μg/mL) respectively. A dose of 160 μg/mL of the methanol extract significantly (P<0.05) resulted in (60.00 ± 5.78) % mortality rate within 90 minutes, and (100.00 ± 0.00) % mortality as the dose was double (320 μg/mL) after 120 minutes. Conclusion:These thus indicate the presence of phytochemicals in E. praetermissaleaf with cytotoxic potential.
Background:In 2020, the World Health Organization urged nations to take domestic steps to curb the spread and contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, also referred to as coronavirus disease 2019 (COVID-19). In the meantime, there was growing clinical evidence that reported favourable effects of using herbal medicine in managingCOVID-19. We, therefore, repurposed Nibima (a Cryptolepis sanguinolenta-based herbal preparation) as an adjunct to conventional therapy for COVID-19. This was premised on our previous in vitroinvestigations that showed that Nibima has both antiviral and anti-inflammatory activities. Materials and Methods:This trial (FDA/CT/11) was an open-label, randomised controlled phase II pilot study, which was conducted from March 2021 to October 2022 among hospitalised COVID-19 patients in the Ashanti Region of Ghana. Participants were either randomised to aqua(water)or Nibima,the investigational product as adjunct to COVID therapy. Results:Nibima was well tolerated by the study participants, and the patients who were administered that together with the standard COVID-19 therapy had rapid clinical recovery compared to those taking aqua and the standardorconventional COVID-19 therapy. The evidence obtained provides a strong basis for future studies with large numbers of hospitalised patients with COVID-19 and other viral respiratory infections. Article HistoryReceived: June 11th2024Revised Received: April 13th2025 Accepted:April 14th2025Published Online: Aug. 29th2025 2Conclusion: Though COVID-19 is no longer a pandemic, it is still a public health challenge. We recommend that Nibima be further investigated for its broad-spectrum antiviral and immunomodulatory activities against SARS-COV-2 and other viral infections in preparedness for the re-emergence of future pandemics